Acetylcysteine sodium (DrugBank: Acetylcysteine)
17 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
6 | パーキンソン病 | 0 |
13 | 多発性硬化症/視神経脊髄炎 | 0 |
19 | ライソゾーム病 | 0 |
20 | 副腎白質ジストロフィー | 0 |
34 | 神経線維腫症 | 0 |
49 | 全身性エリテマトーデス | 0 |
51 | 全身性強皮症 | 0 |
58 | 肥大型心筋症 | 0 |
85 | 特発性間質性肺炎 | 0 |
90 | 網膜色素変性症 | 0 |
94 | 原発性硬化性胆管炎 | 0 |
111 | 先天性ミオパチー | 0 |
164 | 眼皮膚白皮症 | 0 |
193 | プラダー・ウィリ症候群 | 0 |
233 | ウォルフラム症候群 | 0 |
298 | 遺伝性膵炎 | 0 |
299 | 嚢胞性線維症 | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2016-000354-35-DK (EUCTR) | 12/05/2016 | 10/02/2016 | High dose antioxidant treatment of patients with cystic fibrosis evaluated by measuring desmosine/isodesmosine in urine | High dose antioxidant treatment of patients with cystic fibrosis evaluated by measuring desmosine/isodesmosine in urine | cystic fibrosis MedDRA version: 19.0;Level: LLT;Classification code 10068288;Term: Cystic fibrosis pulmonary exacerbation;System Organ Class: 100000004862;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Mucolysin INN or Proposed INN: ACETYLCYSTEINE SODIUM Trade Name: AAC Hexal INN or Proposed INN: ACETYLCYSTEINE SODIUM | Aarhus University Hospital | NULL | Not Recruiting | Female: yes Male: yes | Phase 2 | Denmark |